Polmacoxib

Polmacoxib

File:Polmacoxib.svg
Systematic (IUPAC) name
4-(3-(3-Fluorophenyl)-5,5-dimethyl-4-oxo-4,5-dihydrofuran-2-yl)-benzenesulfonamide
Clinical data
Trade names	Acelex
Identifiers
CAS Number	301692-76-2
PubChem	CID: 9841854
ChemSpider	8017569
UNII	IJ34D6YPAO
ChEMBL	CHEMBL166863
Synonyms	CG100649
Chemical data
Formula	C12H16FNO4S
Molecular mass	361.3914 g/mol
SMILES CC1(C(=O)C(=C(O1)C2=CC=C(C=C2)S(=O)(=O)N)C3=CC(=CC=C3)F)C
InChI InChI=1S/C18H16FNO4S/c1-18(2)17(21)15(12-4-3-5-13(19)10-12)16(24-18)11-6-8-14(9-7-11)25(20,22)23/h3-10H,1-2H3,(H2,20,22,23) Key:IJWPAFMIFNSIGD-UHFFFAOYSA-N

Polmacoxib (Acelex) is a nonsteroidal anti-inflammatory drug (NSAID) used to treat osteoarthritis. It was developed as CG100649 and approved for use in South Korea in February 2015. It inhibits the enzymes carbonic anhydrase and COX-2. A study in healthy volunteers showed drug effects on urinary prostaglandin metabolites for both CG100649 and celecoxib that suggest a similar cardiovascular risk profile. Further work by this group developed dose-exposure relationsships of CG100649 to guide clinical development strategies.

See also

• Tilmacoxib
• Cimicoxib
• NS-398
• Celecoxib